- Home
- CATO vs BTAI Comparison
CATO vs BTAI Comparison
Compare CATO & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CATO | BTAI |
|---|---|---|
| Founded | 1946 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6M | 35.6M |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CATO | BTAI |
|---|---|---|
| Price | $2.99 | $1.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.33 |
| AVG Volume (30 Days) | 47.9K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.09 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $649,806,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $261.81 |
| P/E Ratio | $11.88 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.19 | $1.17 |
| 52 Week High | $4.92 | $8.08 |
Technical Indicators
Market Signals| Indicator | CATO | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 45.50 | 47.35 |
| Support Level | $2.83 | $1.50 |
| Resistance Level | $3.30 | $2.18 |
| Average True Range (ATR) | 0.19 | 0.14 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 19.65 | 34.21 |
Price Performance
Historical ComparisonAbout CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.